Mesothelioma Survival: 18-Year Survivor's Story
Diagnosed with peritoneal mesothelioma at 21 while pregnant, Tamron Little shares her 18-year journey and the reality of long-term survivorship.
When Tamron Little was 21 years old and pregnant, an ultrasound revealed something unexpected. What doctors initially thought was a fibroid tumor turned out to be peritoneal mesothelioma, a rare cancer affecting the lining of the abdomen. She was given 18 months to live. Eighteen years later, she is cancer-free, a mother of four, and a patient advocate whose story challenges the bleakest assumptions about this disease.
Her account, shared with CURE Today, offers one of the most detailed glimpses into what long-term mesothelioma survivorship actually looks like.
A Diagnosis No One Expected
Peritoneal mesothelioma, which affects the abdominal lining, accounts for approximately 300 new diagnoses in the US each year. It is rarer than the pleural form but has significantly better survival outcomes when treated with cytoreductive surgery combined with heated intraperitoneal chemotherapy (HIPEC).
Little’s case was complicated by her pregnancy. She had to wait until five months after giving birth to undergo a 12-hour HIPEC surgery, a procedure that removes visible tumors from the abdominal cavity and then bathes the area in heated chemotherapy to kill remaining cancer cells.
The Treatment That Changed Her Odds
HIPEC combined with cytoreductive surgery has transformed outcomes for peritoneal mesothelioma. Five-year survival rates at specialized centers range from 65% to 80%, a stark contrast to the 10% five-year survival rate for pleural mesothelioma. Women with peritoneal mesothelioma show nearly triple the five-year survival rate compared to men, according to published studies.
Little’s surgery was successful, but the treatment came with lasting consequences. She developed chronic kidney disease from the heated chemotherapy, a known long-term complication of HIPEC. Her experience illustrates a reality that survival statistics alone do not capture: long-term survivorship often means living with the permanent effects of aggressive treatment.
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a two-part procedure. Surgeons first remove all visible tumors from the abdominal cavity (cytoreductive surgery), then circulate heated chemotherapy directly in the abdomen for up to two hours. The heat makes cancer cells more vulnerable to the drugs while limiting systemic side effects. At specialized centers, this approach has produced five-year survival rates of 65% to 80% for peritoneal mesothelioma.
What 18 Years of Survival Looks Like
Long-term survival does not mean the disease disappears. For Little, the years since treatment have involved ongoing monitoring, periodic scans, and the constant possibility of recurrence. She has also navigated parenthood while managing a chronic health condition, ultimately having three more children after her diagnosis.
Her experience over 18 years has included:
- Multiple follow-up surgeries and monitoring scans
- Permanent changes in digestion and daily function from HIPEC
- Chronic kidney disease requiring ongoing management
- Raising four children while living with a cancer diagnosis
- Becoming a patient advocate to help others facing the same journey
“Survivors need to share their stories and make their voices heard,” Little has said, describing her transition from patient to advocate. She began publicly sharing her experience in 2018, more than a decade after her diagnosis.
Why Her Story Matters
Mesothelioma survival stories challenge the narrative that this cancer is always fatal within months. While aggressive disease still claims many patients quickly, advances in treatment, particularly HIPEC for peritoneal mesothelioma, have created a growing population of long-term survivors whose experiences are not reflected in older statistics.
These stories matter because they demonstrate the importance of seeking evaluation at specialized mesothelioma centers like Memorial Sloan Kettering, MD Anderson, Mount Sinai, and MedStar Washington Hospital Center, where access to HIPEC, clinical trials, and multidisciplinary care can significantly affect outcomes. Little’s case also highlights how a second opinion changed the course of her life, after the initial misdiagnosis of a fibroid tumor.
Reader Q&A
Frequently Asked Questions
Who is Tamron Little?
Tamron Little is an 18-year peritoneal mesothelioma survivor who was diagnosed at age 21 in 2007 while pregnant. She was initially misdiagnosed with a fibroid tumor. Given 18 months to live, she underwent a 12-hour HIPEC surgery and has been cancer-free for more than 18 years. She is now a mother of four and a patient advocate.
What is the survival rate for peritoneal mesothelioma?
Peritoneal mesothelioma treated with HIPEC and cytoreductive surgery has five-year survival rates ranging from 65% to 80% at specialized centers. This is significantly better than pleural mesothelioma, which has an approximately 10% five-year survival rate. Women show nearly triple the five-year survival rate compared to men.
What are the long-term effects of HIPEC treatment?
HIPEC can produce long-term side effects including chronic kidney disease (from heated chemotherapy), permanent changes in digestion and bowel function, and the need for ongoing monitoring for recurrence. Tamron Little developed chronic kidney disease as a result of her treatment, illustrating that survivorship often involves managing lasting health consequences.
How rare is peritoneal mesothelioma?
Peritoneal mesothelioma accounts for approximately 300 new diagnoses in the US each year, making it rarer than pleural mesothelioma. It develops in the lining of the abdomen and is primarily linked to asbestos exposure, though the pathway by which asbestos fibers reach the peritoneum is not fully understood.
What is life expectancy after HIPEC?
HIPEC, or hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery, shows varying median survival for people with peritoneal mesothelioma, typically 2.9 to 5 years in selected cases, compared to 6-12 months without it. Studies report 1-year survival rates around 77% and 5-year rates from 6-31%, depending on tumor removal completeness, cancer stage, and patient health. Outcomes improve with optimal cytoreduction, though individual results differ widely. Primary sources like peer-reviewed journals confirm these ranges from clinical data.
What is HIPEC treatment for mesothelioma?
HIPEC, or hyperthermic intraperitoneal chemotherapy, treats peritoneal mesothelioma by combining cytoreductive surgery to remove visible tumors with a heated chemotherapy solution circulated directly in the abdominal cavity. The heat enhances drug penetration and kills remaining microscopic cancer cells while allowing higher doses than systemic chemotherapy with fewer body-wide effects. Studies report 5-year survival rates of 37-50% overall, up to 84.6% with complete cytoreduction, and median survival of 38-67 months for people with peritoneal mesothelioma. This approach is most effective for early-stage cases with epithelioid histology and low tumor burden.
Why is HIPEC controversial?
HIPEC (hyperthermic intraperitoneal chemotherapy) is controversial due to limited high-level evidence, with most data from retrospective case series rather than randomized controlled trials comparing it to standard treatments. Studies report perioperative morbidity of 12-49% and mortality of 3-5%, often linked to cytoreductive surgery but including HIPEC-related renal and hematological toxicity. A phase 2 randomized trial in platinum-sensitive recurrent ovarian cancer showed no survival or progression-free survival benefit from adding HIPEC to cytoreductive surgery. Lack of consensus on indications across cancer types, high costs, and procedural complexity further fuel debate, though it is more accepted for pseudomyxoma peritonei and low-grade appendiceal tumors.
Is mesothelioma one of the worst cancers?
Mesothelioma ranks among the deadliest cancers due to its low 5-year survival rate of 7.2-12% across stages, lower than most others except pancreatic cancer at 7.3%. Localized pleural mesothelioma, the most common type affecting over 75-80% of people with the disease, has a 20% 5-year survival rate, dropping to 8% for distant spread. Median life expectancy after diagnosis ranges from 12-21 months with treatment, often shorter without it, reflecting its aggressive nature linked to asbestos exposure. Factors like stage at diagnosis and treatment access influence individual outcomes.